00:00:0000:00:04
[Animated intro sequence where Zepbound logo and disclaimers appear.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

PP-ZP-US-0452 03/2024 ©Lilly USA, LLC 2024. All rights reserved.

 

This promotional activity was created under the direction and sponsorship of Lilly USA, LLC, and is intended for US healthcare professionals only.

Speaker was paid for his time by Lilly USA, LLC.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

 

00:00:0400:01:00
[Animated sequence where Zepbound Indication, Limitations of Use, and Boxed Warning appear. Zepbound Indication, Limitations of Use, and Boxed Warning remain onscreen until voiceover concludes.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Getting Patients Started on Zepbound^® (tirzepatide):
Treatment Initiation and Experience

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

VOICEOVER:

Zepbound is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

• 30 kilograms per meter squared or greater (obesity) or

• 27 kilograms per meter squared or greater (overweight) in the presence of at least one weight-related comorbid condition (for example, hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).

Limitations of Use:¹

• Zepbound contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

• The safety and efficacy of Zepbound in combination with other products intended for weight management, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

• Zepbound has not been studied in patients with a history of pancreatitis.

00:01:0000:01:55
[Animated sequence where Zepbound Boxed Warning appears. Boxed Warning remains onscreen until voiceover concludes.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Select Important Safety Information¹
Boxed Warning

1. Zepbound. Prescribing Information. Lilly USA, LLC.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

VOICEOVER:
Important Safety Information for Zepbound (tirzepatide) injection.

WARNING: RISK OF THYROID C-CELL TUMORS
In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Zepbound and inform them of symptoms of thyroid tumors (for example, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Zepbound.

00:01:5500:03:12
[Dr. Ethan Lazarus walks into an unadorned room. A gallery wall is behind him with “Welcome”, his title, and affiliation illuminated by a gallery light. He remains standing, addressing the camera. After a few moments, the camera zooms in to his face and “Welcome”, his title, and his affiliation fade offscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Welcome

Dr. Ethan Lazarus, MD
Obesity Medicine, Family Medicine Physician
Clinical Nutrition Center, Greenwood Village, CO

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Hello, my name is Dr. Ethan Lazarus. Since 2004, I've been a physician at, and owner of, Clinical Nutrition Center, an obesity medicine practice in Greenwood Village, Colorado. I've devoted my career, as an obesity medicine and family medicine certified physician, to helping my patients with weight management. My practice focuses on medically supervised weight management strategies and the management of obesity as a medical condition. When it comes to caring for my patients, my goals include offering practical treatment options addressing the factors influencing their health, and providing them valuable education and resources. To achieve these goals effectively, I like to thoroughly research the safety of potential treatments and engage with my peers to learn best practices and useful tips for helping people living with obesity. You probably share the same goals, which is why I'm excited to be with you here today, answering some frequently asked questions about Zepbound. Zepbound has been approved by the US Food and Drug Administration.

00:03:1200:03:26
[The camera begins on Dr. Lazarus’s face and then pans right until he is offscreen. An animated list appears, with “Treatment and Initiation” highlighted, and “Safety Profile” lightly greyed out.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Treatment and Initiation
Safety Profile

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS (offscreen):
As you consider Zepbound for your patients, you may have some questions about treatment initiation, continuation and safety profile. In this video, we'll be answering questions about getting your patients started on Zepbound.

00:03:2600:03:30
[The camera pans back out to Dr. Lazarus and then zooms in to the question onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

What are the available doses for Zepbound?

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
What are the available doses for Zepbound?

00:03:3000:03:41
[Dr. Lazarus addresses the camera as a visual appears next to him, illustrating the pens for the six different doses of Zepbound. He points to the pens as he describes the different dose strengths.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

 

Multiple Doses to Help Individualize Treatment with Zepbound¹
Consider treatment response and tolerability when selecting maintenance dosage¹

For adults with obesity (BMI of ≥30 kg/m²), or with overweight (BMI of ≥27 kg/m²) with at least 1 weight-related comorbidity.¹

The 2.5 mg dosage is for treatment initiation and is not intended for chronic weight management.²

1. Zepbound. Prescribing Information. Lilly USA, LLC.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Zepbound is available in six different doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg.

00:03:4200:03:47
[Dr. Lazarus addresses the camera as the next question appears onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

What doses should be used to start and continue patients on Zepbound?

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
What doses should be used to start and continue patients on Zepbound?

00:03:4700:04:31
[Dr. Lazarus disappears offscreen as the bulleted caption and an animated infographic, depicting the dose-escalation scheme for Zepbound, appear.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Starting and Continuing Zepbound¹
A once-weekly subcutaneous injection¹

Recommended maintenance dosages are 5 mg, 10 mg, or 15 mg¹:

• Initiate with the 2.5-mg dose

• After 4 weeks, increase to the 5-mg dose

• You can continue to increase the dose by 2.5-mg increments after at least 4 weeks on the current dose. The maximum dose is 15 mg

• Consider treatment response and tolerability when selecting maintenance dosage. If not tolerated, consider a lower maintenance dosage

For adults with obesity (BMI of ≥30 kg/m^2) or with overweight (BMI of ≥27 kg/m^2) with at least 1 weight-related comorbidity.¹

The 2.5-mg dosage is for treatment initiation and is not intended for chronic weight management.¹

1. Zepbound. Prescribing Information. Lilly USA, LLC.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS (offscreen):
Recommended maintenance dosages are 5 mg, 10 mg, or 15 mg. Initiate with the 2.5-mg dose. After 4 weeks, increase to the 5-mg dose. You can continue to increase the dose by 2.5-mg increments, after at least 4 weeks on the current dose. The maximum dose is 15 mg. Consider treatment response, and tolerability when selecting maintenance dosage. If not tolerated, consider a lower maintenance dosage. I would also like to emphasize that the 2.5-mg dosage is for treatment initiation and is not intended for chronic weight management.

00:04:3100:04:35
[Dr. Lazarus narrates from offscreen as the next question appears onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

When should Zepbound be administered? What if patients miss a dose?

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS (offscreen):
When should Zepbound be administered? What if patients miss a dose?

00:04:3600:05:00
[Dr. Lazarus narrates from offscreen as the first part of the answer—“Administer Zepbound at any time of day, with or without meals¹”—appears onscreen. The first part of the answer disappears, and Dr. Lazarus appears back onscreen, addressing the camera as he answers the question about missed doses.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Administer Zepbound at any time of day, with or without meals¹

1. Zepbound. Prescribing Information. Lilly USA, LLC.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Administer Zepbound once weekly at any time of day, with or without meals. If a dose is missed, Zepbound should be administered as soon as possible within 4 days, or 96 hours, after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.

00:05:0000:05:11
[Dr. Lazarus appears next to an animated list with the words “Treatment and Initiation” lightly greyed out and “Safety Profile” highlighted. Dr. Lazarus addresses the camera.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Treatment and Initiation
Safety Profile

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
I hope we've addressed some common questions about initiating patients on Zepbound. I'll now answer some questions you may have about the safety and potential side effects of Zepbound.

00:05:1200:05:14
[Dr. Lazarus addresses the camera as he voices the question, which appears onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Are there any contraindications for Zepbound?

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Are there any contraindications for Zepbound?

00:05:1400:05:42
[Dr. Lazarus addresses the camera while he narrates the answer, which appears onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with MEN-2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Zepbound. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with tirzepatide.¹

1. Zepbound. Prescribing Information. Lilly USA, LLC.
MEN 2=Multiple Endocrine Neoplasia syndrome type 2; MTC=medullary thyroid carcinoma.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Zepbound. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with tirzepatide.

00:05:4200:06:11
[Dr. Lazarus starts off-camera as he reads the question, which appears onscreen. Then he appears onscreen next to the question, providing the answer.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

What are the most common adverse reactions observed in Zepbound clinical trials?

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
What are the most common adverse reactions observed in Zepbound clinical trials? The most common adverse reactions reported in 5% or more of patients treated with Zepbound are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and gastroesophageal reflux disease.

00:06:1100:06:22
[Dr. Lazarus addresses the camera as the contact information for Eli Lilly and Company and the FDA appear onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

To report any suspected adverse reactions, contact Eli Lilly and Company at

1-800-LillyRx (1-800-545-5979)

or

FDA at 1-800-FDA-1088 or www.fda.gov/medwatch¹

1. Zepbound. Prescribing Information. Lilly USA, LLC.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
To report any suspected adverse reactions, contact Eli Lilly and Company or the FDA at the numbers and website shown on screen.

00:06:2200:06:27
[From offscreen, Dr. Lazarus poses the question that appears onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Are there any helpful tips for patients as we get them started on Zepbound?

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Are there any helpful tips for patients as we get them started on Zepbound?

00:06:27 00:07:30
[Offscreen, Dr. Lazarus narrates the answer as a bulleted list of helpful tips appears onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

For adults with obesity (BMI of ≥30 kg/m²), or with overweight (BMI of ≥27 kg/m²) with at least 1 weight-related comorbidity.¹

Remind patients that Zepbound is administered using a single-dose pen. There is no need to see or handle the needle.^2,∗

 

Advise patients to read the Instructions for Use.³

 

Allow patients to practice the injection using the demonstration device.

 

Consider having patients administer the first dose in the office.

 

Discuss safety profile and that Zepbound may cause some side effects.^†

 

For example, patients may experience nausea, diarrhea, or vomiting.¹ In order to mitigate these gastrointestinal side effects, they may find it helpful to^4-6:

 

• Eat smaller meals—suggest that they split 3 daily meals into 4 or more smaller meals

• Stop eating when they feel full

• Avoid fatty foods

• Try eating bland foods

 

Encourage patients to continue to drink plenty of water and eat healthy meals to ensure they meet their needs for protein, micronutrients, fiber, and fluids.

 

*If a dose is missed, instruct patients to administer Zepbound as soon as possible within 4 days after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.

^†Side effects may vary and should be evaluated by the healthcare provider for appropriate management.

 

1. Zepbound. Prescribing Information. Lilly USA, LLC.

2. Zepbound. Instructions for Use. Lilly USA, LLC.

3. Zepbound. Medication Guide. Lilly USA, LLC.

4. Maceira E, et al. Ann Palliat Med. 2012;1(2):161-176.

5. Kruger DF, et al. Diabetes Educ. 2010;36(3):44S-72S.

6. Reid TS. Clin Diabetes. 2013;31(4):148-157.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Here are some recommendations that may be helpful for our patients. Remind patients that Zepbound is administered using a single-dose pen. There is no need to see or handle the needle. Advise patients to read the Instructions for Use. Allow patients to practice the injection using the demonstration device. Consider having patients administer the first dose in the office. Discuss safety profile and that Zepbound may cause some side effects. For example, patients may experience nausea, diarrhea, or vomiting. In order to mitigate these gastrointestinal side effects, they may find it helpful to eat smaller meals - suggest that they split three daily meals into four or more smaller meals. Stop eating when they feel full. Avoid fatty foods. Try eating bland foods. Encourage patients to continue to drink plenty of water and eat healthy meals to ensure they meet their needs for protein, micronutrients, fiber, and fluids.

00:07:3000:07:34
[From offscreen, Dr. Lazarus poses the question that appears onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Are there any considerations for pregnant women?

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Are there any considerations for pregnant women?

00:07:3400:08:25
[From offscreen, Dr. Lazarus provides the answer, which appears onscreen as the question disappears.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue Zepbound when a pregnancy is recognized. Available data with tirzepatide in pregnant patients are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy.¹

There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Zepbound (tirzepatide) during pregnancy. Pregnant patients exposed to Zepbound and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).¹

1. Zepbound. Prescribing Information. Lilly USA, LLC.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue Zepbound when a pregnancy is recognized. Available data with tirzepatide in pregnant patients are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy. There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Zepbound (tirzepatide) during pregnancy. Pregnant patients exposed to Zepbound, and healthcare providers, are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).

00:08:2500:08:29
[From offscreen, Dr. Lazarus poses the question that appears onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Are there any considerations for mothers who are breastfeeding?

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Are there any considerations for mothers who are breastfeeding?

00:08:2900:08:53
[From offscreen, Dr. Lazarus provides the answer, which appears onscreen as the question disappears.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

There are no data on the presence of tirzepatide or its metabolites in animal or human milk, the effects on the breastfed infant, or the effects on milk production.¹

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Zepbound and any potential adverse effects on the breastfed infant from Zepbound or from the underlying maternal condition.¹

1. Zepbound. Prescribing Information. Lilly USA, LLC.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
There are no data on the presence of tirzepatide or its metabolites in animal or human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Zepbound and any potential adverse effects on the breastfed infant from Zepbound or from the underlying maternal condition.

00:08:5400:08:59
[From offscreen, Dr. Lazarus poses the question that appears onscreen.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Are there any concerns regarding taking oral contraceptives while on Zepbound?

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Are there any concerns regarding taking oral contraceptives while on Zepbound?

00:08:5900:09:29
[The camera zooms out to show Dr. Lazarus. The response appears next to him onscreen, and he addresses the camera.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Use of Zepbound may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time.¹

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation with Zepbound and for 4 weeks after each dose escalation.¹

1. Zepbound. Prescribing Information. Lilly USA, LLC.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Use of Zepbound may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation with Zepbound and for 4 weeks after each dose escalation.

00:09:2900:09:52
[The camera zooms in to Dr. Lazarus’s face as he concludes the video. An icon of a patient being supported in the palms of a provider appears with the text, “Supported and Empowered”.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Supported and Empowered

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
Keeping patients informed about the initiation, administration, and safety profile of their treatment, and engaging them effectively, may help them feel supported and empowered throughout their treatment journey. I hope we have helped address some of the common questions about initiation and safety considerations that you and your patients may have about Zepbound.

00:09:5200:10:09
[The camera zooms out to show a wide shot of the gallery wall. The Zepbound logo and copyright information appear underneath a gallery light.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

If you have any additional questions, or want more information, please visit Zepbound.lilly.com/HCP

Zepbound^® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

DR. LAZARUS:
If you have additional questions about getting your patients started, including the efficacy and safety profile of this treatment, please visit the Zepbound website for detailed information. You may also review the US Prescribing Information. Thank you for joining us to learn more about Zepbound.

00:10:0900:18:00
[The Major Statement of Risk fills the screen and remains onscreen until voiceover concludes.]

CAPTION:
once weekly Zepbound^® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

ZP HCP MSR 08NOV2023

1. Zepbound. Prescribing Information. Lilly USA, LLC.

Please see Important Safety Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer within this video, and the full Prescribing Information and Medication Guide by clicking the links on this page.

VOICEOVER:
Zepbound is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kilograms per meter squared or greater (obesity) or 27 kilograms per meter squared or greater (overweight) in the presence of at least one weight-related comorbid condition (for example, hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). Zepbound contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. The safety and efficacy of Zepbound in combination with other products intended for weight management, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. Zepbound has not been studied in patients with a history of pancreatitis.

WARNING: Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.

Severe Gastrointestinal Disease: Use of Zepbound has been associated with gastrointestinal adverse reactions, sometimes severe. Zepbound has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.

Acute Kidney Injury: Use of Zepbound has been associated with acute kidney injury, which can result from dehydration due to gastrointestinal adverse reactions to Zepbound; including nausea, vomiting, and diarrhea. Monitor renal function in patients reporting adverse reactions to Zepbound that could lead to volume depletion.

Acute Gallbladder Disease: Treatment with Zepbound and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease. In clinical trials of Zepbound, cholelithiasis was reported in 1.1% of Zepbound-treated patients and 1% of placebo-treated patients, cholecystitis was reported in 0.7% of Zepbound-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of Zepbound-treated patients and no placebo-treated patients. Acute gallbladder events were associated with weight reduction. If cholecystitis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.

Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or tirzepatide. Pancreatitis has been reported in Zepbound clinical trials. If pancreatitis is suspected, discontinue Zepbound and initiate appropriate management. If the diagnosis of pancreatitis is confirmed, Zepbound should not be restarted.

Hypersensitivity Reactions: There have been postmarketing reports of serious hypersensitivity reactions (for example, anaphylaxis, angioedema) in patients treated with tirzepatide. If hypersensitivity reactions occur, advise patients to promptly seek medical attention and discontinue use of Zepbound. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in Zepbound. Use caution in patients with a history of anaphylaxis or angioedema with a GLP-1 receptor agonist. It is unknown if such patients will be predisposed to these reactions with Zepbound.

Hypoglycemia: Zepbound lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes mellitus and BMI greater than or equal to 27 kilograms per meter squared, hypoglycemia (plasma glucose less than 54 milligrams per deciliter) was reported in 4.2% of Zepbound-treated patients versus 1.3% of placebo-treated patients. In this trial, patients taking Zepbound in combination with an insulin secretagogue (for example, sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to Zepbound-treated patients not taking a sulfonylurea (2.1%). Hypoglycemia has also been associated with Zepbound and GLP-1 receptor agonists in adults without type 2 diabetes mellitus. There is also increased risk of hypoglycemia in patients treated with tirzepatide in combination with insulin. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. In patients with diabetes mellitus, monitor blood glucose prior to starting Zepbound and during Zepbound treatment. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.

Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus: Tirzepatide has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.

Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other chronic weight management products. Monitor patients treated with Zepbound for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior. Discontinue Zepbound in patients who experience suicidal thoughts or behaviors. Avoid Zepbound in patients with a history of suicidal attempts or active suicidal ideation.

The most common adverse reactions, reported in ≥5% of patients treated with Zepbound are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease.

Drug Interactions: When initiating Zepbound, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia. Zepbound delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised. Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (for example, warfarin) when concomitantly administered with Zepbound.

Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue Zepbound. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy.

There are no data on the presence of tirzepatide or its metabolites in animal or human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Zepbound and any potential adverse effects on the breastfed infant from Zepbound or from the underlying maternal condition.

Use of Zepbound may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception, for 4 weeks after initiation with Zepbound and for 4 weeks after each dose escalation.

The safety and effectiveness of Zepbound have not been established in pediatric patients less than 18 years of age.

00:18:0000:18:05
[The Zepbound logo, disclaimers, and Lilly logo appear.]

CAPTION:
PP-ZP-US-0452 03/2024 ©Lilly USA, LLC 2024. All rights reserved.

This promotional activity was created under the direction and sponsorship of Lilly USA, LLC, and is intended for US healthcare professionals only.

Speaker was paid for his time by Lilly USA, LLC.